In a preclinical study conducted on human breast carcinomas from 58 patients, it was observed that the action of 17-β-estradiol altered the expression and/or localization of FGFR2 and that 62% of the tumor cells showed moderate to intense FGFR2 labeling in their cytoplasm [51]. Here, FGFR2 is linked to breast carcinoma.